Gvoke(Glucagon)
XERS
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Xeris Biopharma Holdings, Inc.
$964K
Medicare cost, 2024
$964K
Medicare cost, 2024
Medicare drug plans spent $963,881 on Gvoke (glucagon) in 2024, for 2,163 prescriptions and refills filled by 1,557 patients. Spending rose 54% from 2023 to 2024. Ohio accounts for the most spending ($153,428, 16% of the total). It is made by Xeris Biopharma Holdings, Inc. (XERS).
Medicare cost, 2024
$964K
+54.3% from 2023
Prescriptions
2,163
$445.62 per claim
Patients
1,557
1,204 prescribers
Total spending, 2024
$964K
$619.06 per patient
Questions and answers
How much does Medicare spend on Gvoke?
Medicare prescription drug plans paid $964K for Gvoke in 2024, for 2,163 prescriptions and refills to 1,557 patients (up 54.3% from 2023). The average cost per claim was $445.62.
Which state spends the most on Gvoke?
Ohio had the highest Medicare cost for Gvoke in 2024: $153K for 158 claims, followed by New York ($80K).
Who prescribes Gvoke the most?
Angela J Houfek, physician assistant in Green Bay, WI, had the highest Medicare cost for Gvoke in 2024: 20 claims costing $12K.
Who makes Gvoke?
Gvoke is made by Xeris Biopharma Holdings, Inc. (XERS), listed in the Medicare spending data as Xeris Pharmaceu.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Gvoke was $964K in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Gvoke, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Angela J Houfek Green Bay, WI | Physician Assistant | 20 | 19 | $12K |
| Keyna I Schlup Whitefish, MT | Family Practice | 28 | Under 11 | $10K |
| Reema A Patel Old Bridge, NJ | Endocrinology | 21 | 16 | $9,366 |
| Stella Ilyayeva Rego Park, NY | Internal Medicine | 24 | 12 | $9,236 |
| Kristyn S Stevens Sylva, NC | Nurse Practitioner | 14 | Under 11 | $8,323 |
| Paul Y Casanova-Romero Port St Lucie, FL | Endocrinology | 25 | 20 | $8,275 |
| Marie-Noel Rahhal Twinsburg, OH | Endocrinology | 15 | 13 | $8,042 |
| Kelby F Bethards Fort Collins, CO | Family Practice | 13 | Under 11 | $7,016 |
| Rafael O Robledo Hammond, LA | Internal Medicine | 20 | Under 11 | $6,178 |
| Jose F Bonelli Silver Spring, MD | Internal Medicine | 17 | 12 | $5,216 |
| Elizabeth H Harris Charlotte, NC | Endocrinology | 11 | Under 11 | $4,662 |
| Karthik Subbu Geneva, IL | Internal Medicine | 15 | 14 | $4,639 |
| Mary Capelety Avon, OH | Nurse Practitioner | 11 | Under 11 | $4,048 |
| Sonum Singh Chadds Ford, PA | Internal Medicine | 14 | Under 11 | $3,926 |
| James G Hamilton Jr. Demorest, GA | Family Practice | 11 | Under 11 | $3,689 |
| Lubaina S Presswala New York, NY | Endocrinology | 11 | Under 11 | $3,246 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 410 | 545 | 471 | $215K |
| 2023 | 896 | 1,419 | 1,079 | $625K |
| 2024 | 1,204 | 2,163 | 1,557 | $964K |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Xeris Pharmaceu | 2,163 | $964K |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 4,235 side-effect reports named glucagon, the active ingredient of Gvoke (reports from 2004 on). 3,277 of them (77.4%) were serious, 676 named a death and 2,037 named a hospital stay. The reactions named most often were drug ineffective, dyspnoea and acute kidney injury. 1,739 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
4,235
392 in 2025 (+6.2% from 2024)
Serious
77.4%
3,277 reports
Deaths named
676
16.0% of reports
Hospital stays
2,037
48.1% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Gvoke?
4,235 reports from 2004 through September 2026 named glucagon, the active ingredient of Gvoke. 3,277 of them (77.4%) were serious, 676 named a death and 2,037 named a hospital stay.
What are the most reported side effects of Gvoke?
389 reports named drug ineffective, the reaction named most often, followed by dyspnoea (375) and acute kidney injury (324). In the last 5 years the reaction named most often was dyspnoea (229 reports). A report can name several reactions.
How many side-effect reports named Gvoke in 2025?
392 reports were received in 2025 (+6.2% from 2024). 2026 so far: 264 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Gvoke caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Gvoke caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with glucagon: Gvoke Hypopen 2-Pack, Baqsimi, Glucagon Emergency Kit, Gvoke Hypopen 1-Pack, Glucagen, Gvoke Pfs 1-Pack Syringe, Gvoke Pfs 2-Pack Syringe
- Makers on the stock market:
NVO
XERS·NVO drug pipeline - Drug approvals (1 approval on file for glucagon) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (glucagon) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.